793 related articles for article (PubMed ID: 25573840)
1. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
3. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
Spalding JR; Hay J
Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
[TBL] [Abstract][Full Text] [Related]
6. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
11. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
15. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
17. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
20. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
